All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MDS Hub

MDS Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2019-06-26T14:47:16.000Z

ICML 2019 | Efficacy of novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for R/R NHL

By Iqra Farooq, Michael Dickinson
Featured
Michael Dickinson
Jun 26, 2019
Share:

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, AU, about the efficacy of the novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL).

Michael Dickinson describes CD20-TCB as a CD20 CD3 bispecific antibody, which was tested in non-Hodgkin lymphoma, targeting CD20. Despite toxicities being observed in patients, it is still early days, with promising results for patients with a very aggressive refractory condition.

ICML 2019 | Efficacy of novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for R/R NHL

More about...
Aggressive B-cell lymphomasChronic lymphocytic leukemiaChronic lymphocytic leukemiasDiffuse large B-cell lymphomaFollicular lymphomaHairy cell leukemiaICML 2019Indolent B-cell lymphomasMantle cell lymphomaMantle cell lymphomasTransformed follicular lymphoma

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

What kind of 1L DLBCL patients should now be treated with Pola-R-CHP (choose all options that apply)?
4 votes - 1 day left ...

Related articles

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox